Evaluation of a Sarcopenia Prediction Model and Development and Effectiveness of a Nursing Guidance Mobile App
May 2, 2022 updated by: Pei-Hung Liao, National Taipei University of Nursing and Health Sciences
We evaluated a model for the prediction of high-risk populations for sarcopenia in home settings, developed a sarcopenia nursing guidance mobile application, and assessed the effectiveness of this application in influencing sarcopenia-related knowledge and self-care behavior among participants.
Study Overview
Status
Enrolling by invitation
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei county, Taiwan, 112
- Cheng Hsin General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
We adopted the convenient sampling method to recruit 120 participants-those who visited the hospital regularly and their accompanying family members
Description
Inclusion criteria were being a member of the public, aged ≥20 years and <80 years, and having experience using mobile devices or smartphones.
Exclusion criteria were not belonging to a high-risk population for sarcopenia and/or being unable to use the application platform.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
one group
Using a one-group pretest-posttest design
|
The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes in sarcopenia-related knowledge and awareness regarding self-care
Time Frame: 2019~2022
|
In this study, the mobile app significantly improved sarcopenia-related knowledge and awareness regarding self-care among the participants
|
2019~2022
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2019
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
May 2, 2022
First Submitted That Met QC Criteria
May 2, 2022
First Posted (Actual)
May 5, 2022
Study Record Updates
Last Update Posted (Actual)
May 5, 2022
Last Update Submitted That Met QC Criteria
May 2, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 108A-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.